



Clinical trial results:

A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy.

Summary

EudraCT number	2007-004458-98
Trial protocol	FR NL PL EE CZ BG DE
Global end of trial date	20 September 2008

Results information

Result version number	v1 (current)
This version publication date	13 April 2016
First version publication date	19 March 2015

Trial information

Trial identification

Sponsor protocol code	FFA109684
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 October 2008
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	20 September 2008
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of this 8-week study is to evaluate the dose response, efficacy and safety of four dosage regimens of GW685698X (200mcg, 400mcg, 600mcg and 800mcg) administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent uncontrolled asthma to effectively select the appropriate dose of GW685698X to be evaluated in further clinical studies.

Protection of trial subjects:

On initial entry into the trial, subjects were assessed for their fitness for the study by a physical exam, chemistry/hematology/urinalysis laboratory tests, and serum pregnancy (females of child-bearing potential). Medical, asthma and previous treatment histories were obtained along with pulmonary function testing. Reversibility was also established. Stability limits of 80% of the subject's FEV1 and peak expiratory flow (PEF) rate were established at the randomization visit to assist the investigators in monitoring subjects' asthma status throughout the study. Twice each day (morning and evening), subjects rated their asthma symptoms and measured their PEF. Subjects were instructed to contact the investigator if the PEF fell below the established limit. Albuterol inhalation was provided for rescue use and use was monitored each morning and evening when the other assessments were performed. Pulmonary function was assessed at each visit via spirometry. Vital signs were also taken at each visit and the subjects were questioned in regard to their health and adverse events/serious adverse events that may have occurred. Two medics supported the study and were available for consultation with the investigators as needed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 December 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 41
Country: Number of subjects enrolled	Poland: 56
Country: Number of subjects enrolled	Bulgaria: 68
Country: Number of subjects enrolled	Czech Republic: 4
Country: Number of subjects enrolled	Estonia: 12
Country: Number of subjects enrolled	France: 20
Country: Number of subjects enrolled	Germany: 64
Country: Number of subjects enrolled	Australia: 26
Country: Number of subjects enrolled	Canada: 61
Country: Number of subjects enrolled	Chile: 132
Country: Number of subjects enrolled	Mexico: 80

Country: Number of subjects enrolled	Peru: 75
Country: Number of subjects enrolled	Russian Federation: 93
Country: Number of subjects enrolled	South Africa: 55
Country: Number of subjects enrolled	Thailand: 41
Country: Number of subjects enrolled	United States: 347
Worldwide total number of subjects	1175
EEA total number of subjects	265

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	62
Adults (18-64 years)	1000
From 65 to 84 years	113
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants (par.) meeting eligibility criteria at the Screening visit completed a 28-day Run-in Period for Baseline safety evaluations and measures of asthma status. Par. were then randomized to an 8-week Treatment Period. 1175 par. were screened, and 627 par. were randomized, out of which 622 par. received at least one dose of study treatment.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Respiratory use

Dosage and administration details:

Twice daily

Arm title	GW685698X 200 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 200 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Respiratory use

Dosage and administration details:

200 µg once daily

Arm title	GW685698X 400 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Respiratory use

Dosage and administration details:

400 µg once daily

Arm title	GW685698X 600 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 600 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Respiratory use

Dosage and administration details:

600 µg once daily

Arm title	GW685698X 800 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 800 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Respiratory use

Dosage and administration details:

800 µg once daily

Arm title	FP 500 µg BID
------------------	---------------

Arm description:

Participants received fluticasone propionate (FP) 500 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Arm type	Active comparator
Investigational medicinal product name	Fluticasone propionate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Respiratory use

Dosage and administration details:

500 µg twice daily

Number of subjects in period 1^[1]	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD
Started	103	99	101
Completed	65	81	93
Not completed	38	18	8
Physician decision	1	-	-
Consent withdrawn by subject	1	-	-
Adverse event, non-fatal	2	3	-
Lost to follow-up	-	1	1
Lack of efficacy	34	11	6
Protocol deviation	-	3	1

Number of subjects in period 1^[1]	GW685698X 600 µg OD	GW685698X 800 µg OD	FP 500 µg BID
Started	107	102	110
Completed	94	85	97
Not completed	13	17	13
Physician decision	-	1	-
Consent withdrawn by subject	1	3	1
Adverse event, non-fatal	1	-	4
Lost to follow-up	-	-	-
Lack of efficacy	11	12	8
Protocol deviation	-	1	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 1175 par. were screened, and 627 par. were randomized, out of which 622 par. received at least one dose of study treatment. Subject disposition is presented for the 622 participants that received at least one dose of study treatment.

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 200 µg OD
Reporting group description: Participants received GW685698X 200 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 400 µg OD
Reporting group description: Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 600 µg OD
Reporting group description: Participants received GW685698X 600 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 800 µg OD
Reporting group description: Participants received GW685698X 800 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	FP 500 µg BID
Reporting group description: Participants received fluticasone propionate (FP) 500 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	

Reporting group values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD
Number of subjects	103	99	101
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	47.2 ± 14.03	45.7 ± 15.02	47.2 ± 14.39
Gender categorical Units: Subjects			
Female	64	63	62
Male	39	36	39

Race			
Units: Subjects			
African American/African Heritage (HER)	2	3	3
American Indian or Alaska Native	6	7	5
Central/South Asian HER	2	3	1
Japanese/East Asian HER/South East Asian HER	4	6	6
White	83	74	80
American Indian or Alaska Native & Asian & White	0	1	0
American Indian or Alaska Native & White	6	5	6
Missing	0	0	0

Reporting group values	GW685698X 600 µg OD	GW685698X 800 µg OD	FP 500 µg BID
Number of subjects	107	102	110
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	45.7	46.6	46.1
standard deviation	± 14.38	± 14.09	± 13.86
Gender categorical			
Units: Subjects			
Female	67	63	68
Male	40	39	42
Race			
Units: Subjects			
African American/African Heritage (HER)	4	4	4
American Indian or Alaska Native	8	5	7
Central/South Asian HER	4	1	1
Japanese/East Asian HER/South East Asian HER	7	6	6
White	77	80	83
American Indian or Alaska Native & Asian & White	0	0	0
American Indian or Alaska Native & White	7	6	8
Missing	0	0	1

Reporting group values	Total		
Number of subjects	622		
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		

Gender categorical			
Units: Subjects			
Female	387		
Male	235		
Race			
Units: Subjects			
African American/African Heritage (HER)	20		
American Indian or Alaska Native	38		
Central/South Asian HER	12		
Japanese/East Asian HER/South East Asian HER	35		
White	477		
American Indian or Alaska Native & Asian & White	1		
American Indian or Alaska Native & White	38		
Missing	1		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 200 µg OD
Reporting group description: Participants received GW685698X 200 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 400 µg OD
Reporting group description: Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 600 µg OD
Reporting group description: Participants received GW685698X 600 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	GW685698X 800 µg OD
Reporting group description: Participants received GW685698X 800 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	
Reporting group title	FP 500 µg BID
Reporting group description: Participants received fluticasone propionate (FP) 500 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.	

Primary: Mean change from Baseline in trough (evening pre-dose and pre- rescue bronchodilator) FEV1 at Week 8

End point title	Mean change from Baseline in trough (evening pre-dose and pre- rescue bronchodilator) FEV1 at Week 8
End point description: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Pre-dose and pre-rescue bronchodilator (albuterol/salbutamol) trough FEV1 (the measurement of FEV1 performed at the end of the dosing interval) was measured electronically by spirometry in the evening at BL through Week 8 clinic visits. The highest of 3 technically acceptable measurements was recorded. The Visit 3 FEV1 assessment was used as the BL value. Change from BL in trough FEV1 was calculated as the value at WK 8 minus the value at BL. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of BL trough FEV1, country, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-BL on-treatment measurement (scheduled and unscheduled visits) was used to impute missing measurements.	
End point type	Primary

End point timeframe:

Baseline (BL) and Week (WK) 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[1]	99 ^[2]	101 ^[3]	107 ^[4]
Units: Liters				
least squares mean (standard error)	-0.043 (± 0.0338)	0.232 (± 0.0347)	0.229 (± 0.0342)	0.221 (± 0.0332)

Notes:

[1] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication

[2] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication

[3] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication

[4] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[5]	110 ^[6]		
Units: Liters				
least squares mean (standard error)	0.182 (± 0.0342)	0.155 (± 0.0332)		

Notes:

[5] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication

[6] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication

Statistical analyses

Statistical analysis title	Analysis 1
Comparison groups	GW685698X 200 µg OD v Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.275
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.18
upper limit	0.37

Statistical analysis title	Analysis 2
----------------------------	------------

Comparison groups	Placebo v GW685698X 400 µg OD
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.272
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.178
upper limit	0.367

Statistical analysis title	Analysis 3
Comparison groups	Placebo v GW685698X 600 µg OD
Number of subjects included in analysis	210
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.264
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.171
upper limit	0.357

Statistical analysis title	Analysis 4
Comparison groups	Placebo v GW685698X 800 µg OD
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.225
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.131
upper limit	0.32

Statistical analysis title	Analysis 5
Comparison groups	Placebo v FP 500 µg BID
Number of subjects included in analysis	213
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.198
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.105
upper limit	0.291

Secondary: Mean change from Baseline in daily trough (pre-dose and pre-rescue bronchodilator) evening peak expiratory flow (PEF) averaged over the 8-week Treatment Period

End point title	Mean change from Baseline in daily trough (pre-dose and pre-rescue bronchodilator) evening peak expiratory flow (PEF) averaged over the 8-week Treatment Period
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is defined as the maximal rate (speed) that a person can exhale during a short maximal expiratory effort after a full inspiration. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three attempts was recorded by the participants in a daily diary. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily evening PEF over the 8-week treatment period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline trough evening PEF, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100 ^[7]	99 ^[8]	101 ^[9]	107 ^[10]
Units: Liters per minute				
least squares mean (standard error)	-5.1 (± 3.32)	11.9 (± 3.32)	14.5 (± 3.29)	11.7 (± 3.2)

Notes:

[7] - ITT Population. Only those participants available at the specified time points were analyzed.

[8] - ITT Population. Only those participants available at the specified time points were analyzed.

[9] - ITT Population. Only those participants available at the specified time points were analyzed.

[10] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
-------------------------	------------------------	---------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101 ^[11]	109 ^[12]		
Units: Liters per minute				
least squares mean (standard error)	16.3 (± 3.3)	11.1 (± 3.17)		

Notes:

[11] - ITT Population. Only those participants available at the specified time points were analyzed.

[12] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in daily morning PEF averaged over the 8-week Treatment Period

End point title	Mean change from Baseline in daily morning PEF averaged over the 8-week Treatment Period
-----------------	------------------------------------------------------------------------------------------

End point description:

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is defined as the maximal rate (speed) that a person can exhale during a short maximal expiratory effort after a full inspiration. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three attempts was recorded by the participants in a daily diary. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily morning PEF over the 8-week treatment period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline trough morning PEF, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101 ^[13]	99 ^[14]	101 ^[15]	107 ^[16]
Units: Liters per minute				
least squares mean (standard error)	-7.3 (± 3.32)	19.6 (± 3.34)	20.9 (± 3.31)	16.7 (± 3.22)

Notes:

[13] - ITT Population. Only those participants available at the specified time points were analyzed.

[14] - ITT Population. Only those participants available at the specified time points were analyzed.

[15] - ITT Population. Only those participants available at the specified time points were analyzed.

[16] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101 ^[17]	109 ^[18]		
Units: Liters per minute				
least squares mean (standard error)	20.7 (± 3.32)	16.5 (± 3.19)		

Notes:

[17] - ITT Population. Only those participants available at the specified time points were analyzed.

[18] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in the percentage of symptom-free 24-hour (hr) periods during the 8-week Treatment Period

End point title	Mean change from Baseline in the percentage of symptom-free 24-hour (hr) periods during the 8-week Treatment Period
-----------------	---------------------------------------------------------------------------------------------------------------------

End point description:

Asthma symptoms were recorded in a daily diary by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom-free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 8-week Treatment Period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101 ^[19]	99 ^[20]	101 ^[21]	107 ^[22]
Units: Percentage of symptom-free 24-hr periods				
least squares mean (standard error)	6.4 (± 2.71)	20.1 (± 2.74)	19.6 (± 2.71)	15.1 (± 2.63)

Notes:

[19] - ITT Population. Only those participants available at the specified time points were analyzed.

[20] - ITT Population. Only those participants available at the specified time points were analyzed.

[21] - ITT Population. Only those participants available at the specified time points were analyzed.

[22] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101 ^[23]	110 ^[24]		
Units: Percentage of symptom-free 24-hr periods				
least squares mean (standard error)	18.5 (± 2.71)	15.4 (± 2.61)		

Notes:

[23] - ITT Population. Only those participants available at the specified time points were analyzed.

[24] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in the percentage of rescue-free 24-hour (hr) periods during the 8-week Treatment Period

End point title	Mean change from Baseline in the percentage of rescue-free 24-hour (hr) periods during the 8-week Treatment Period
-----------------	--------------------------------------------------------------------------------------------------------------------

End point description:

The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue-free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 8-week Treatment Period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101 ^[25]	99 ^[26]	101 ^[27]	107 ^[28]
Units: Percentage of rescue-free 24-hr periods				
least squares mean (standard error)	3.6 (± 2.75)	17.9 (± 2.78)	21.2 (± 2.75)	17.4 (± 2.67)

Notes:

[25] - ITT Population. Only those participants available at the specified time points were analyzed.

[26] - ITT Population. Only those participants available at the specified time points were analyzed.

[27] - ITT Population. Only those participants available at the specified time points were analyzed.

[28] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101 ^[29]	110 ^[30]		
Units: Percentage of rescue-free 24-hr periods				
least squares mean (standard error)	22.3 (± 2.75)	16.7 (± 2.63)		

Notes:

[29] - ITT Population. Only those participants available at the specified time points were analyzed.

[30] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number participants who withdrew due to lack of efficacy during the 8-week Treatment Period

End point title	Number participants who withdrew due to lack of efficacy during the 8-week Treatment Period
-----------------	---------------------------------------------------------------------------------------------

End point description:

The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of the study medication up to Week 8/Early Withdrawal

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[31]	99 ^[32]	101 ^[33]	107 ^[34]
Units: Participants	34	11	6	11

Notes:

[31] - ITT Population

[32] - ITT Population

[33] - ITT Population

[34] - ITT Population

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[35]	110 ^[36]		
Units: Participants	12	8		

Notes:

[35] - ITT Population

[36] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with any on-treatment adverse event or serious adverse event throughout the 8-week Treatment Period

End point title	Number of participants with any on-treatment adverse event or serious adverse event throughout the 8-week Treatment Period
-----------------	----------------------------------------------------------------------------------------------------------------------------

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold $\geq 3\%$) and SAEs.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of the study medication up to Week 8/Early Withdrawal

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[37]	99 ^[38]	101 ^[39]	107 ^[40]
Units: Participants				
Any AE	23	31	34	37
Any SAE	1	2	0	1

Notes:

[37] - ITT Population

[38] - ITT Population

[39] - ITT Population

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[41]	110 ^[42]		
Units: Participants				
Any AE	36	39		
Any SAE	0	2		

Notes:

[41] - ITT Population

[42] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with clinical/visual evidence of oropharyngeal candidiasis

End point title	Number of participants with clinical/visual evidence of oropharyngeal candidiasis
End point description:	A detailed oropharyngeal examination for visual evidence of oral candidiasis was performed.
End point type	Secondary
End point timeframe:	From Baseline up to Week 8/Early Withdrawal

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[43]	99 ^[44]	101 ^[45]	107 ^[46]
Units: Participants				
Clinical evidence	0	0	0	0
No clinical evidence	103	99	101	107

Notes:

[43] - ITT Population

[44] - ITT Population

[45] - ITT Population

[46] - ITT Population

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[47]	110 ^[48]		
Units: Participants				
Clinical evidence	0	0		
No clinical evidence	102	110		

Notes:

[47] - ITT Population

[48] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in the blood at Baseline and Week 8

End point title	Percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in the blood at Baseline and Week 8
-----------------	-------------------------------------------------------------------------------------------------------------------------

End point description:

Blood samples were collected for the measurement of the percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in the blood at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[49]	99 ^[50]	101 ^[51]	107 ^[52]
Units: Percentage in the blood				
arithmetic mean (standard deviation)				
Basophils, BL, n=96, 98, 96, 101, 96, 104	0.31 (± 0.211)	0.38 (± 0.315)	0.35 (± 0.252)	0.34 (± 0.306)
Basophils, W8, n=64, 78, 86, 88, 80, 93	0.38 (± 0.191)	0.35 (± 0.199)	0.28 (± 0.172)	0.26 (± 0.164)
Eosinophils, BL, n=96, 98, 96, 101, 96, 104	4.21 (± 3.241)	4.11 (± 3.024)	3.7 (± 2.942)	4.34 (± 3.148)
Eosinophils, W 8, n=64, 78, 86, 88, 80, 93	3.92 (± 2.835)	3.54 (± 2.784)	2.76 (± 1.943)	2.94 (± 3.395)
Lymphocytes, BL, n=96, 98, 96, 101, 96, 104	32.23 (± 7.231)	32.31 (± 8.344)	33.48 (± 9.299)	32.03 (± 7.813)
Lymphocytes, W 8, n=64, 78, 86, 88, 80, 93	30.87 (± 8.332)	30.64 (± 7.046)	30.28 (± 8.734)	27.64 (± 9.216)
Monocytes, BL, n=96, 98, 96, 101, 96, 104	5.03 (± 2.337)	4.75 (± 1.765)	5.23 (± 2.58)	4.89 (± 1.896)
Monocytes, W 8, n=64, 78, 86, 88, 80, 93	5.07 (± 1.885)	4.53 (± 2.025)	4.82 (± 2.087)	4.5 (± 2.188)
Total neutrophils, BL, n=96, 98, 96, 101, 96, 104	58.22 (± 8.02)	58.45 (± 9.166)	57.08 (± 10.168)	58.41 (± 8.589)
Total neutrophils, W8, n=64, 78, 86, 88, 80, 93	59.78 (± 9.101)	60.95 (± 7.819)	61.87 (± 9.175)	64.67 (± 10.031)

Notes:

[49] - ITT Population. Only those participants available at the specified time points were analyzed.

[50] - ITT Population. Only those participants available at the specified time points were analyzed.

[51] - ITT Population. Only those participants available at the specified time points were analyzed.

[52] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[53]	110 ^[54]		
Units: Percentage in the blood				
arithmetic mean (standard deviation)				
Basophils, BL, n=96, 98, 96, 101, 96, 104	0.36 (± 0.22)	0.34 (± 0.181)		
Basophils, W8, n=64, 78, 86, 88, 80, 93	0.31 (± 0.175)	0.3 (± 0.159)		
Eosinophils, BL, n=96, 98, 96, 101, 96, 104	3.74 (± 2.543)	3.5 (± 2.675)		
Eosinophils, W 8, n=64, 78, 86, 88, 80, 93	2.14 (± 2.076)	3.31 (± 2.815)		
Lymphocytes, BL, n=96, 98, 96, 101, 96, 104	33.33 (± 7.99)	30.13 (± 8.938)		
Lymphocytes, W 8, n=64, 78, 86, 88, 80, 93	29.5 (± 9.763)	29.23 (± 8.205)		
Monocytes, BL, n=96, 98, 96, 101, 96, 104	5.19 (± 2.384)	5.06 (± 1.989)		
Monocytes, W 8, n=64, 78, 86, 88, 80, 93	4.64 (± 2.224)	4.97 (± 2.15)		
Total neutrophils, BL, n=96, 98, 96, 101, 96, 104	57.33 (± 8.627)	60.96 (± 10.096)		
Total neutrophils, W8, n=64, 78, 86, 88, 80, 93	63.41 (± 10.926)	62.19 (± 9.128)		

Notes:

[53] - ITT Population. Only those participants available at the specified time points were analyzed.

[54] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Hematocrit at Baseline and Week 8

End point title	Hematocrit at Baseline and Week 8
End point description:	
Blood samples were collected for the measurement of hematocrit at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[55]	99 ^[56]	101 ^[57]	107 ^[58]
Units: Proportion of 1				
arithmetic mean (standard deviation)				
BL, n=95, 98, 96, 100, 94, 104	0.43 (± 0.039)	0.43 (± 0.034)	0.42 (± 0.035)	0.42 (± 0.042)
W8, n=64, 78, 86, 89, 80, 93	0.43 (± 0.04)	0.42 (± 0.036)	0.42 (± 0.035)	0.42 (± 0.042)

Notes:

[55] - ITT Population. Only those participants available at the specified time points were analyzed.

[56] - ITT Population. Only those participants available at the specified time points were analyzed.

[57] - ITT Population. Only those participants available at the specified time points were analyzed.

[58] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[59]	110 ^[60]		
Units: Proportion of 1				
arithmetic mean (standard deviation)				
BL, n=95, 98, 96, 100, 94, 104	0.43 (± 0.038)	0.42 (± 0.043)		
W8, n=64, 78, 86, 89, 80, 93	0.43 (± 0.037)	0.42 (± 0.043)		

Notes:

[59] - ITT Population. Only those participants available at the specified time points were analyzed.

[60] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Hemoglobin at Baseline and Week 8

End point title	Hemoglobin at Baseline and Week 8
End point description:	
Blood samples were collected for the measurement of hemoglobin at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[61]	99 ^[62]	101 ^[63]	107 ^[64]
Units: Grams per liter (G/L)				
arithmetic mean (standard deviation)				
BL, n=95, 98, 96, 100, 94, 104	139.99 (± 13.23)	140.2 (± 11.183)	139.35 (± 11.577)	138.5 (± 14.987)
W8, n=64, 78, 86, 89, 80, 93	139.63 (± 12.359)	137.42 (± 11.461)	137.56 (± 11.747)	135.81 (± 13.847)

Notes:

[61] - ITT Population. Only those participants available at the specified time points were analyzed.

[62] - ITT Population. Only those participants available at the specified time points were analyzed.

[63] - ITT Population. Only those participants available at the specified time points were analyzed.

[64] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[65]	110 ^[66]		

Units: Grams per liter (G/L)				
arithmetic mean (standard deviation)				
BL, n=95, 98, 96, 100, 94, 104	140.91 (\pm 13.023)	138.53 (\pm 14.77)		
W8, n=64, 78, 86, 89, 80, 93	140.64 (\pm 12.679)	137.31 (\pm 14.65)		

Notes:

[65] - ITT Population. Only those participants available at the specified time points were analyzed.

[66] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Platelet count and white blood cell count at Baseline and Week 8

End point title	Platelet count and white blood cell count at Baseline and Week 8
-----------------	------------------------------------------------------------------

End point description:

Blood samples were collected for determining the platelet count and white blood cell (WBC) count at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[67]	99 ^[68]	101 ^[69]	107 ^[70]
Units: 10 ⁹ cells per liter (GI/L)				
arithmetic mean (standard deviation)				
Platelet count, BL, n=95, 98, 96, 99, 94, 104	275.76 (\pm 58.949)	281.46 (\pm 74.55)	270.32 (\pm 50.756)	275.62 (\pm 56.811)
Platelet count, W8, n=64, 78, 86, 89, 79, 93	265.86 (\pm 55.155)	285.62 (\pm 66.487)	270.77 (\pm 50.491)	291.36 (\pm 63.65)
WBC count, BL, n=95, 98, 96, 99, 94, 104	8.16 (\pm 2.182)	7.77 (\pm 2.016)	8.01 (\pm 2.199)	8.18 (\pm 1.807)
WBC count, W8, n=64, 78, 86, 88, 80, 93	7.84 (\pm 1.944)	7.97 (\pm 1.671)	8.38 (\pm 2.416)	9.1 (\pm 2.134)

Notes:

[67] - ITT Population. Only those participants available at the specified time points were analyzed.

[68] - ITT Population. Only those participants available at the specified time points were analyzed.

[69] - ITT Population. Only those participants available at the specified time points were analyzed.

[70] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[71]	110 ^[72]		
Units: 10 ⁹ cells per liter (GI/L)				
arithmetic mean (standard deviation)				
Platelet count, BL, n=95, 98, 96, 99, 94, 104	269.09 (\pm 61.89)	269.8 (\pm 65.376)		

Platelet count, W8, n=64, 78, 86, 89, 79, 93	280.78 (\pm 65.044)	275.48 (\pm 65.011)		
WBC count, BL, n=95, 98, 96, 99, 94, 104	7.91 (\pm 1.853)	8.25 (\pm 2.4)		
WBC count, W8, n=64, 78, 86, 88, 80, 93	8.9 (\pm 1.964)	8.21 (\pm 1.973)		

Notes:

[71] - ITT Population. Only those participants available at the specified time points were analyzed.

[72] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Red blood cell count at Baseline and Week 8

End point title	Red blood cell count at Baseline and Week 8
End point description:	
Blood samples were collected for determining the red blood cell count at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[73]	99 ^[74]	101 ^[75]	107 ^[76]
Units: 10 ¹² cells per liter (TI/L)				
arithmetic mean (standard deviation)				
BL, n=95, 98, 96, 100, 94, 104	4.67 (\pm 0.413)	4.69 (\pm 0.438)	4.64 (\pm 0.413)	4.6 (\pm 0.428)
W8, n=64, 78, 86, 89, 80, 93	4.61 (\pm 0.423)	4.64 (\pm 0.472)	4.57 (\pm 0.383)	4.52 (\pm 0.442)

Notes:

[73] - ITT Population. Only those participants available at the specified time points were analyzed.

[74] - ITT Population. Only those participants available at the specified time points were analyzed.

[75] - ITT Population. Only those participants available at the specified time points were analyzed.

[76] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[77]	110 ^[78]		
Units: 10 ¹² cells per liter (TI/L)				
arithmetic mean (standard deviation)				
BL, n=95, 98, 96, 100, 94, 104	4.66 (\pm 0.416)	4.64 (\pm 0.421)		
W8, n=64, 78, 86, 89, 80, 93	4.65 (\pm 0.425)	4.61 (\pm 0.43)		

Notes:

[77] - ITT Population. Only those participants available at the specified time points were analyzed.

[78] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

Secondary: Clinical chemistry parameters of alanine amino transferase (ALT), alkaline phosphatase (ALP), aspartate amino transferase (AST), gamma glutamyl transferase (GGT), and lactate dehydrogenase (LDH) at Baseline and Week 8

End point title	Clinical chemistry parameters of alanine amino transferase (ALT), alkaline phosphatase (ALP), aspartate amino transferase (AST), gamma glutamyl transferase (GGT), and lactate dehydrogenase (LDH) at Baseline and Week 8
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Blood samples were collected for the measurement of ALT, ALP, AST, GGT, and LDH at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[79]	99 ^[80]	101 ^[81]	107 ^[82]
Units: International units per liter (IU/L)				
arithmetic mean (standard deviation)				
ALT, BL, n=101, 97, 101, 107, 101, 109	22.4 (± 12.52)	21 (± 10.02)	23.9 (± 15.07)	23.5 (± 18.89)
ALT, W8, n=66, 79, 91, 90, 86, 96	23.7 (± 19.99)	20.2 (± 11.31)	21.6 (± 14.43)	20.4 (± 12.33)
ALP, BL, n=101, 97, 101, 107, 100, 109	74.7 (± 21.34)	80.2 (± 41.24)	90.9 (± 54.98)	77.1 (± 38.35)
ALP, W8, n=66, 78, 91, 89, 86, 96	75.1 (± 21.38)	80.4 (± 54.47)	86.6 (± 42.66)	74.5 (± 26.54)
AST, BL, n=101, 97, 100, 106, 101, 108	21.6 (± 6.45)	21.6 (± 7.11)	23.7 (± 10.46)	23.3 (± 20.15)
AST, W8, n=66, 78, 91, 89, 85, 96	24.1 (± 20.87)	21.6 (± 8.39)	22 (± 11.41)	22.1 (± 17.12)
GGT, BL, n=101, 97, 101, 107, 101, 109	33 (± 26.34)	36.8 (± 39.79)	40.4 (± 44.86)	42.3 (± 109.34)
GGT, W8, n=66, 79, 91, 90, 86, 96	36.4 (± 37.07)	32.7 (± 22.5)	40.6 (± 70.55)	47.4 (± 167.46)
LDH, BL, n=101, 97, 100, 106, 101, 108	158.2 (± 26.1)	162 (± 27.64)	163.5 (± 35.16)	158.7 (± 30.24)
LDH, W8, n=66, 78, 91, 89, 85, 96	160.4 (± 43.44)	159 (± 27.52)	163.6 (± 37)	164.6 (± 35.8)

Notes:

[79] - ITT Population. Only those participants available at the specified time points were analyzed.

[80] - ITT Population. Only those participants available at the specified time points were analyzed.

[81] - ITT Population. Only those participants available at the specified time points were analyzed.

[82] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[83]	110 ^[84]		
Units: International units per liter (IU/L)				
arithmetic mean (standard deviation)				
ALT, BL, n=101, 97, 101, 107, 101, 109	23.1 (± 14.71)	20.5 (± 13.26)		
ALT, W8, n=66, 79, 91, 90, 86, 96	22 (± 12.14)	20.7 (± 14.56)		
ALP, BL, n=101, 97, 101, 107, 100, 109	73.9 (± 31.02)	76.7 (± 32.97)		
ALP, W8, n=66, 78, 91, 89, 86, 96	70.6 (± 26.33)	77.2 (± 28.25)		

AST, BL, n=101, 97, 100, 106, 101, 108	22.7 (± 8.42)	21.9 (± 11.34)		
AST, W8, n=66, 78, 91, 89, 85, 96	22 (± 9.25)	21.4 (± 8.61)		
GGT, BL, n=101, 97, 101, 107, 101, 109	31.2 (± 22.88)	28.2 (± 20.5)		
GGT, W8, n=66, 79, 91, 90, 86, 96	34.1 (± 28.31)	29.2 (± 20.01)		
LDH, BL, n=101, 97, 100, 106, 101, 108	161.6 (± 31.49)	160.6 (± 24.97)		
LDH, W8, n=66, 78, 91, 89, 85, 96	170.6 (± 33.92)	164 (± 27.59)		

Notes:

[83] - ITT Population. Only those participants available at the specified time points were analyzed.

[84] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical chemistry parameters of albumin and total protein at Baseline and Week 8

End point title	Clinical chemistry parameters of albumin and total protein at Baseline and Week 8
End point description:	Blood samples were collected for the measurement of albumin and total protein at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[85]	99 ^[86]	101 ^[87]	107 ^[88]
Units: Grams per liter (g/L)				
arithmetic mean (standard deviation)				
Albumin, BL, n=101, 97, 101, 107, 101, 109	44.6 (± 2.36)	44.9 (± 3.11)	45.1 (± 2.91)	44.3 (± 3.27)
Albumin, W8, n=66, 79, 91, 90, 86, 96	44.5 (± 2.66)	44.8 (± 3.27)	44.6 (± 3.32)	44 (± 3.28)
Total protein, BL, n=101, 97, 101, 107, 101, 109	72.7 (± 3.82)	73.4 (± 3.9)	73.2 (± 4.15)	73.3 (± 4.22)
Total protein, W8, n=66, 79, 91, 90, 86, 96	72 (± 4.21)	72.6 (± 3.67)	72.7 (± 4.54)	72.2 (± 4.2)

Notes:

[85] - ITT Population. Only those participants available at the specified time points were analyzed.

[86] - ITT Population. Only those participants available at the specified time points were analyzed.

[87] - ITT Population. Only those participants available at the specified time points were analyzed.

[88] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[89]	110 ^[90]		
Units: Grams per liter (g/L)				
arithmetic mean (standard deviation)				

Albumin, BL, n=101, 97, 101, 107, 101, 109	44.8 (± 3.49)	44.9 (± 2.96)		
Albumin, W8, n=66, 79, 91, 90, 86, 96	44.1 (± 3.38)	44.6 (± 3.07)		
Total protein, BL, n=101, 97, 101, 107, 101, 109	73.1 (± 4.8)	72.5 (± 3.85)		
Total protein, W8, n=66, 79, 91, 90, 86, 96	72 (± 4.39)	71.9 (± 4.34)		

Notes:

[89] - ITT Population. Only those participants available at the specified time points were analyzed.

[90] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical chemistry parameters of calcium, carbon dioxide content/bicarbonate, chloride, cholesterol, glucose, phosphorus inorganic, potassium, sodium, and urea at Baseline and Week 8

End point title	Clinical chemistry parameters of calcium, carbon dioxide content/bicarbonate, chloride, cholesterol, glucose, phosphorus inorganic, potassium, sodium, and urea at Baseline and Week 8
End point description:	Blood samples were collected for the measurement of calcium, carbon dioxide content/bicarbonate (CO ₂ /BI), chloride, cholesterol, glucose, phosphorus inorganic (PI), potassium, sodium, and urea at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[91]	99 ^[92]	101 ^[93]	107 ^[94]
Units: Millimoles per liter (mmol/L)				
arithmetic mean (standard deviation)				
Calcium, BL, n=101, 97, 100, 106, 101, 108	2.3 (± 0.07)	2.3 (± 0.1)	2.4 (± 0.09)	2.3 (± 0.09)
Calcium, W8, n=66, 78, 91, 89, 85, 96	2.3 (± 0.09)	2.3 (± 0.11)	2.4 (± 0.1)	2.3 (± 0.11)
CO ₂ /BI, BL, n=101, 97, 100, 106, 101, 108	23.2 (± 2.45)	22.9 (± 2.75)	23.3 (± 2.39)	22.6 (± 2.87)
CO ₂ /BI, W8, n=66, 78, 91, 89, 85, 96	22.7 (± 3.01)	22.7 (± 2.68)	23.5 (± 2.71)	22.6 (± 2.56)
Chloride, BL, n=101, 97, 101, 107, 101, 109	104.8 (± 2.45)	104.4 (± 2.24)	104.1 (± 2.84)	104.3 (± 2.24)
Chloride, W8, n=66, 79, 91, 90, 86, 96	105 (± 2.52)	104.4 (± 2.46)	103.9 (± 2.84)	104.3 (± 2.46)
Cholesterol, BL, n=101, 97, 101, 107, 101, 109	5.4 (± 1.04)	5.3 (± 1.11)	5.3 (± 1.13)	5.3 (± 1.21)
Cholesterol, W8, n=66, 79, 91, 90, 86, 96	5.3 (± 1)	5.2 (± 1.09)	5.2 (± 1.07)	5.4 (± 1.24)
Glucose, BL, n=101, 97, 101, 107, 101, 109	5.3 (± 0.81)	5.5 (± 2.36)	5.2 (± 1.27)	5.2 (± 1.14)
Glucose, W8, n=66, 78, 91, 90, 86, 96	5.2 (± 1.38)	5.3 (± 1.81)	5.5 (± 3.24)	5.2 (± 1.19)
PI, BL, n=101, 97, 101, 107, 101, 109	1.1 (± 0.18)	1.1 (± 0.18)	1.2 (± 0.22)	1.2 (± 0.19)
PI, W8, n=66, 79, 91, 90, 86, 96	1.2 (± 0.16)	1.2 (± 0.17)	1.2 (± 0.15)	1.2 (± 0.16)

Potassium, BL, n=101, 97, 100, 106, 101, 108	4.2 (± 0.38)	4.3 (± 0.47)	4.2 (± 0.51)	4.2 (± 0.41)
Potassium, W8, n=66, 78, 91, 89, 85, 96	4.2 (± 0.36)	4.2 (± 0.6)	4.2 (± 0.41)	4.2 (± 0.38)
Sodium, BL, n=101, 97, 101, 107, 101, 109	140.8 (± 1.93)	140.4 (± 1.92)	140.4 (± 2.06)	140.1 (± 1.93)
Sodium, W8, n=66, 79, 91, 90, 86, 96	140.5 (± 2.15)	140.3 (± 2.17)	140.3 (± 2.09)	140.1 (± 1.99)
Urea, BL, n=101, 97, 101, 107, 101, 109	5.7 (± 1.68)	5.4 (± 1.49)	5.8 (± 1.72)	5 (± 1.34)
Urea, W8, n=66, 79, 91, 90, 86, 96	5.5 (± 1.57)	5.4 (± 1.5)	5.7 (± 1.37)	5.4 (± 1.45)

Notes:

[91] - ITT Population. Only those participants available at the specified time points were analyzed.

[92] - ITT Population. Only those participants available at the specified time points were analyzed.

[93] - ITT Population. Only those participants available at the specified time points were analyzed.

[94] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[95]	110 ^[96]		
Units: Millimoles per liter (mmol/L)				
arithmetic mean (standard deviation)				
Calcium, BL, n=101, 97, 100, 106, 101, 108	2.3 (± 0.09)	2.3 (± 0.09)		
Calcium, W8, n=66, 78, 91, 89, 85, 96	2.3 (± 0.1)	2.3 (± 0.09)		
CO2/BI, BL, n=101, 97, 100, 106, 101, 108	23.1 (± 2.56)	23.2 (± 2.33)		
CO2/BI, W8, n=66, 78, 91, 89, 85, 96	23.3 (± 2.11)	22.9 (± 2.73)		
Chloride, BL, n=101, 97, 101, 107, 101, 109	104.4 (± 2.25)	105 (± 2.8)		
Chloride, W8, n=66, 79, 91, 90, 86, 96	104.1 (± 2.68)	104.9 (± 2.79)		
Cholesterol, BL, n=101, 97, 101, 107, 101, 109	5.5 (± 1.15)	5.1 (± 1.08)		
Cholesterol, W8, n=66, 79, 91, 90, 86, 96	5.5 (± 1.03)	5.2 (± 1.17)		
Glucose, BL, n=101, 97, 101, 107, 101, 109	5.4 (± 1.73)	5.3 (± 0.91)		
Glucose, W8, n=66, 78, 91, 90, 86, 96	5.4 (± 1.91)	5.3 (± 1.16)		
PI, BL, n=101, 97, 101, 107, 101, 109	1.2 (± 0.19)	1.1 (± 0.18)		
PI, W8, n=66, 79, 91, 90, 86, 96	1.2 (± 0.17)	1.2 (± 0.16)		
Potassium, BL, n=101, 97, 100, 106, 101, 108	4.2 (± 0.3)	4.2 (± 0.41)		
Potassium, W8, n=66, 78, 91, 89, 85, 96	4.2 (± 0.32)	4.2 (± 0.36)		
Sodium, BL, n=101, 97, 101, 107, 101, 109	140.1 (± 1.64)	140.8 (± 1.95)		
Sodium, W8, n=66, 79, 91, 90, 86, 96	140.4 (± 2.21)	140.6 (± 2.08)		
Urea, BL, n=101, 97, 101, 107, 101, 109	5.5 (± 1.52)	5.4 (± 1.63)		
Urea, W8, n=66, 79, 91, 90, 86, 96	5.6 (± 1.35)	5.6 (± 1.55)		

Notes:

[95] - ITT Population. Only those participants available at the specified time points were analyzed.

[96] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

Secondary: Clinical chemistry parameters of creatinine, direct bilirubin, total bilirubin, and uric acid at Baseline and Week 8

End point title	Clinical chemistry parameters of creatinine, direct bilirubin, total bilirubin, and uric acid at Baseline and Week 8
End point description:	
Blood samples were collected for the measurement of creatinine, direct bilirubin (DBIL), total bilirubin (TBIL), and uric acid at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[97]	99 ^[98]	101 ^[99]	107 ^[100]
Units: Micromoles per liter (µmol/L)				
arithmetic mean (standard deviation)				
Creatinine, BL, n=101, 97, 101, 107, 101, 109	84.4 (± 14.89)	79.8 (± 14.17)	79.4 (± 15.86)	78.8 (± 14.12)
Creatinine, W8, n=66, 79, 91, 90, 86, 96	83.2 (± 15.84)	79.9 (± 12.4)	78.6 (± 15.25)	78.7 (± 13.95)
DBIL, BL, n=101, 97, 101, 107, 101, 109	2 (± 0.92)	2 (± 1.08)	2.1 (± 1.15)	2 (± 1.05)
DBIL, W8, n=65, 78, 91, 90, 86, 96	1.7 (± 0.75)	1.8 (± 0.91)	2.1 (± 1.19)	1.9 (± 1.22)
TBIL, BL, n=101, 97, 101, 107, 101, 109	9.4 (± 4.67)	9.9 (± 4.87)	9.8 (± 5.19)	9.7 (± 5)
TBIL, W8, n=66, 79, 91, 90, 86, 96	8.3 (± 3.68)	9 (± 4.44)	9.8 (± 5.1)	9.4 (± 5.65)
Uric acid, BL, n=101, 97, 101, 107, 101, 109	323.3 (± 102.51)	326.1 (± 75.18)	330.4 (± 81.69)	322.1 (± 87.22)
Uric acid, W8, n=66, 79, 91, 90, 86, 96	326.2 (± 104.11)	318.5 (± 75.93)	319.2 (± 89.12)	305.8 (± 91.04)

Notes:

[97] - ITT Population. Only those participants available at the specified time points were analyzed.

[98] - ITT Population. Only those participants available at the specified time points were analyzed.

[99] - ITT Population. Only those participants available at the specified time points were analyzed.

[100] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[101]	110 ^[102]		
Units: Micromoles per liter (µmol/L)				
arithmetic mean (standard deviation)				
Creatinine, BL, n=101, 97, 101, 107, 101, 109	81.4 (± 13.9)	82 (± 18.12)		
Creatinine, W8, n=66, 79, 91, 90, 86, 96	81.7 (± 13.87)	83.1 (± 18.02)		
DBIL, BL, n=101, 97, 101, 107, 101, 109	1.7 (± 0.94)	2.1 (± 1.38)		
DBIL, W8, n=65, 78, 91, 90, 86, 96	1.7 (± 0.82)	2 (± 1.2)		

TBIL, BL, n=101, 97, 101, 107, 101, 109	8.2 (± 3.31)	10.3 (± 5.86)		
TBIL, W8, n=66, 79, 91, 90, 86, 96	8.6 (± 3.33)	9.6 (± 4.76)		
Uric acid, BL, n=101, 97, 101, 107, 101, 109	330.8 (± 90.07)	310.6 (± 83.25)		
Uric acid, W8, n=66, 79, 91, 90, 86, 96	316.5 (± 92.8)	322.7 (± 88.44)		

Notes:

[101] - ITT Population. Only those participants available at the specified time points were analyzed.

[102] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated result for the indicated urinalysis parameters tested by dipstick at Baseline and Week 8/Withdrawal

End point title	Number of participants with the indicated result for the indicated urinalysis parameters tested by dipstick at Baseline and Week 8/Withdrawal
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cells (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner; results for urinalysis parameters can be read as 1+, 2+, 3+, Large, Moderate, Negative (Neg), Small, and Trace. For UG, the result can be read as Neg, Trace, Trace or 1/10 grams per deciliter (G/dL), 1+ or 1/4 G/dL, 2+ or 1/2 G/dL, 3+ or 1 G/dL, 4+ or 2 or more G/dL, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had 1+, 2+, 3+, Large, Moderate, Neg, Small, or Trace levels at Baseline (BL) and Week 8 (W8)/Early Withdrawal (EW). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8/Early Withdrawal

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[103]	99 ^[104]	101 ^[105]	107 ^[106]
Units: Participants				
UOB, 1+, BL, n=97, 98, 96, 102, 95, 103	0	3	3	0
UOB, 2+, BL, n=97, 98, 96, 102, 95, 103	3	1	2	1
UOB, 3+, BL, n=97, 98, 96, 102, 95, 103	0	0	4	2
UOB, Large, BL, n=97, 98, 96, 102, 95, 103	0	1	0	1
UOB, Moderate, BL, n=97, 98, 96, 102, 95, 103	1	0	1	0
UOB, Neg, BL, n=97, 98, 96, 102, 95, 103	87	87	81	93
UOB, Small, BL, n=97, 98, 96, 102, 95, 103	0	2	0	0
UOB, Trace, BL, n=97, 98, 96, 102, 95, 103	6	4	5	5

UOB, 1+, W8, n=65, 79, 88, 90, 80, 92	1	0	0	4
UOB, 2+, W8, n=65, 79, 88, 90, 80, 92	0	1	2	3
UOB, 3+, W8, n=65, 79, 88, 90, 80, 92	1	2	3	2
UOB, Large, W8, n=65, 79, 88, 90, 80, 92	0	0	0	1
UOB, Moderate, W8, n=65, 79, 88, 90, 80, 92	0	0	1	1
UOB, Neg, W8, n=65, 79, 88, 90, 80, 92	57	71	75	71
UOB, Small, W8, n=65, 79, 88, 90, 80, 92	0	0	0	1
UOB, Trace, W8, n=65, 79, 88, 90, 80, 92	6	5	7	7
UOB, Neg, EW, n=7, 0, 1, 4, 5, 4	7	0	1	4
UG, 1+ or 1/4 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	0	1	0
UG, 2+ or 1/2 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	0	0	1
UG, 3+ or 1 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	2	0	1
UG, Neg, BL, n=97, 98, 96, 102, 95, 103	97	95	93	99
UG, Trace, BL, n=97, 98, 96, 102, 95, 103	0	0	0	0
UG, Trace or 1/10 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	1	2	1
UG, 1+ or 1/4 G/DL, W8, n=65, 79, 88, 90, 80, 92	0	1	2	1
UG, 3+ or 1 G/DL, W8, n=65, 79, 88, 90, 80, 92	1	0	1	0
UG, 4+ or 2 or more G/DL, W8, n=65, 79, 88, 90, 80, 92	0	1	1	0
UG, Neg, W8, n=65, 79, 88, 90, 80, 92	63	77	83	88
UG, Trace, W8, n=65, 79, 88, 90, 80, 92	0	0	0	1
UG, Trace or 1/10 G/DL, W8, n=65, 79, 88, 90, 80, 92	1	0	1	0
UG, Neg, EW, n=7, 0, 1, 4, 5, 4	7	0	1	4
UK, 1+, BL, n=97, 98, 96, 102, 95, 103	1	0	0	0
UK, Neg, BL, n=97, 98, 96, 102, 95, 103	93	97	93	101
UK, Trace, BL, n=97, 98, 96, 102, 95, 103	3	1	3	1
UK, Neg, W8, n=65, 79, 88, 90, 80, 92	63	78	86	86
UK, Trace, W8, n=65, 79, 88, 90, 80, 92	2	1	2	4
UK, Neg, EW, n=7, 0, 1, 4, 5, 4	7	0	1	4
UP, 1+, BL, n=97, 98, 96, 102, 95, 103	3	3	5	7
UP, 2+, BL, n=97, 98, 96, 102, 95, 103	0	0	3	0
UP, 3+, BL, n=97, 98, 96, 102, 95, 103	0	0	0	1
UP, Neg, BL, n=97, 98, 96, 102, 95, 103	90	84	80	88
UP, Trace, BL, n=97, 98, 96, 102, 95, 103	4	11	8	6
UP, 1+, W8, n=65, 79, 88, 90, 80, 92	1	1	5	5
UP, 2+, W8, n=65, 79, 88, 90, 80, 92	2	0	0	1
UP, 3+, W8, n=65, 79, 88, 90, 80, 92	0	0	0	0
UP, Neg, W8, n=65, 79, 88, 90, 80, 92	56	69	77	77
UP, Trace, W8, n=65, 79, 88, 90, 80, 92	6	9	6	7

UP, Neg, EW, n=7, 0, 1, 4, 5, 4	6	0	0	4
UP, Trace, EW, n=7, 0, 1, 4, 5, 4	1	0	1	0
UWBC, 1+, BL, n=97, 98, 96, 102, 95, 103	3	9	4	9
UWBC, 2+, BL, n=97, 98, 96, 102, 95, 103	1	1	3	1
UWBC, 3+, BL, n=97, 98, 96, 102, 95, 103	0	2	1	0
UWBC, Moderate, BL, n=97, 98, 96, 102, 95, 103	1	1	0	1
UWBC, Neg, BL, n=97, 98, 96, 102, 95, 103	88	78	83	85
UWBC, Small, BL, n=97, 98, 96, 102, 95, 103	0	2	3	0
UWBC, Trace, BL, n=97, 98, 96, 102, 95, 103	4	5	2	6
UWBC, 1+, W8, n=65, 79, 88, 90, 80, 92	3	5	5	8
UWBC, 2+, W8, n=65, 79, 88, 90, 80, 92	0	1	0	2
UWBC, 3+, W8, n=65, 79, 88, 90, 80, 92	0	1	1	1
UWBC, Large, W8, n=65, 79, 88, 90, 80, 92	0	0	0	0
UWBC, Moderate, W8, n=65, 79, 88, 90, 80, 92	1	1	1	1
UWBC, Neg, W8, n=65, 79, 88, 90, 80, 92	58	69	75	72
UWBC, Small, W8, n=65, 79, 88, 90, 80, 92	1	0	0	0
UWBC, Trace, W8, n=65, 79, 88, 90, 80, 92	2	2	6	6
UWBC, 1+, EW, n=7, 0, 1, 4, 5, 4	2	0	0	0
UWBC, Neg, EW, n=7, 0, 1, 4, 5, 4	4	0	1	4
UWBC, Small, EW, n=7, 0, 1, 4, 5, 4	1	0	0	0

Notes:

[103] - ITT Population. Only those participants available at the specified time points were analyzed.

[104] - ITT Population. Only those participants available at the specified time points were analyzed.

[105] - ITT Population. Only those participants available at the specified time points were analyzed.

[106] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[107]	110 ^[108]		
Units: Participants				
UOB, 1+, BL, n=97, 98, 96, 102, 95, 103	1	4		
UOB, 2+, BL, n=97, 98, 96, 102, 95, 103	3	0		
UOB, 3+, BL, n=97, 98, 96, 102, 95, 103	1	1		
UOB, Large, BL, n=97, 98, 96, 102, 95, 103	0	0		
UOB, Moderate, BL, n=97, 98, 96, 102, 95, 103	0	0		
UOB, Neg, BL, n=97, 98, 96, 102, 95, 103	83	95		

UOB, Small, BL, n=97, 98, 96, 102, 95, 103	0	0		
UOB, Trace, BL, n=97, 98, 96, 102, 95, 103	7	3		
UOB, 1+, W8, n=65, 79, 88, 90, 80, 92	1	1		
UOB, 2+, W8, n=65, 79, 88, 90, 80, 92	0	1		
UOB, 3+, W8, n=65, 79, 88, 90, 80, 92	0	2		
UOB, Large, W8, n=65, 79, 88, 90, 80, 92	0	0		
UOB, Moderate, W8, n=65, 79, 88, 90, 80, 92	0	0		
UOB, Neg, W8, n=65, 79, 88, 90, 80, 92	72	79		
UOB, Small, W8, n=65, 79, 88, 90, 80, 92	0	0		
UOB, Trace, W8, n=65, 79, 88, 90, 80, 92	7	9		
UOB, Neg, EW, n=7, 0, 1, 4, 5, 4	5	4		
UG, 1+ or 1/4 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	1		
UG, 2+ or 1/2 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	0		
UG, 3+ or 1 G/DL, BL, n=97, 98, 96, 102, 95, 103	1	0		
UG, Neg, BL, n=97, 98, 96, 102, 95, 103	94	101		
UG, Trace, BL, n=97, 98, 96, 102, 95, 103	0	1		
UG, Trace or 1/10 G/DL, BL, n=97, 98, 96, 102, 95, 103	0	0		
UG, 1+ or 1/4 G/DL, W8, n=65, 79, 88, 90, 80, 92	1	0		
UG, 3+ or 1 G/DL, W8, n=65, 79, 88, 90, 80, 92	1	0		
UG, 4+ or 2 or more G/DL, W8, n=65, 79, 88, 90, 80, 92	0	0		
UG, Neg, W8, n=65, 79, 88, 90, 80, 92	78	90		
UG, Trace, W8, n=65, 79, 88, 90, 80, 92	0	1		
UG, Trace or 1/10 G/DL, W8, n=65, 79, 88, 90, 80, 92	0	1		
UG, Neg, EW, n=7, 0, 1, 4, 5, 4	5	4		
UK, 1+, BL, n=97, 98, 96, 102, 95, 103	1	0		
UK, Neg, BL, n=97, 98, 96, 102, 95, 103	91	99		
UK, Trace, BL, n=97, 98, 96, 102, 95, 103	3	4		
UK, Neg, W8, n=65, 79, 88, 90, 80, 92	78	87		
UK, Trace, W8, n=65, 79, 88, 90, 80, 92	2	5		
UK, Neg, EW, n=7, 0, 1, 4, 5, 4	5	4		
UP, 1+, BL, n=97, 98, 96, 102, 95, 103	3	3		
UP, 2+, BL, n=97, 98, 96, 102, 95, 103	0	0		
UP, 3+, BL, n=97, 98, 96, 102, 95, 103	0	1		
UP, Neg, BL, n=97, 98, 96, 102, 95, 103	85	82		
UP, Trace, BL, n=97, 98, 96, 102, 95, 103	7	17		
UP, 1+, W8, n=65, 79, 88, 90, 80, 92	2	3		

UP, 2+, W8, n=65, 79, 88, 90, 80, 92	0	0		
UP, 3+, W8, n=65, 79, 88, 90, 80, 92	0	1		
UP, Neg, W8, n=65, 79, 88, 90, 80, 92	71	81		
UP, Trace, W8, n=65, 79, 88, 90, 80, 92	7	7		
UP, Neg, EW, n=7, 0, 1, 4, 5, 4	5	4		
UP, Trace, EW, n=7, 0, 1, 4, 5, 4	0	0		
UWBC, 1+, BL, n=97, 98, 96, 102, 95, 103	6	3		
UWBC, 2+, BL, n=97, 98, 96, 102, 95, 103	3	2		
UWBC, 3+, BL, n=97, 98, 96, 102, 95, 103	1	4		
UWBC, Moderate, BL, n=97, 98, 96, 102, 95, 103	0	0		
UWBC, Neg, BL, n=97, 98, 96, 102, 95, 103	83	81		
UWBC, Small, BL, n=97, 98, 96, 102, 95, 103	0	2		
UWBC, Trace, BL, n=97, 98, 96, 102, 95, 103	2	11		
UWBC, 1+, W8, n=65, 79, 88, 90, 80, 92	4	8		
UWBC, 2+, W8, n=65, 79, 88, 90, 80, 92	5	5		
UWBC, 3+, W8, n=65, 79, 88, 90, 80, 92	2	1		
UWBC, Large, W8, n=65, 79, 88, 90, 80, 92	0	1		
UWBC, Moderate, W8, n=65, 79, 88, 90, 80, 92	0	0		
UWBC, Neg, W8, n=65, 79, 88, 90, 80, 92	65	71		
UWBC, Small, W8, n=65, 79, 88, 90, 80, 92	0	1		
UWBC, Trace, W8, n=65, 79, 88, 90, 80, 92	4	5		
UWBC, 1+, EW, n=7, 0, 1, 4, 5, 4	0	0		
UWBC, Neg, EW, n=7, 0, 1, 4, 5, 4	5	4		
UWBC, Small, EW, n=7, 0, 1, 4, 5, 4	0	0		

Notes:

[107] - ITT Population. Only those participants available at the specified time points were analyzed.

[108] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Urine specific gravity at Baseline and Week 8/Early Withdrawal

End point title	Urine specific gravity at Baseline and Week 8/Early Withdrawal
-----------------	----------------------------------------------------------------

End point description:

Urine samples were collected for the measurement of urine specific gravity by dipstick method at Baseline and at Week 8/Early Withdrawal. The Baseline value was the measurement taken at screening (Visit 1). Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020. Please note that for the GW685698X 200 µg OD treatment no participants were analyzed; therefore, the value of 99999 was entered which represents NA. Also for the GW685698X 400 µg OD treatment the standard deviation could not be calculated for a single participant; therefore the value of 99999 was entered which represents NA.

End point type	Secondary
End point timeframe:	
Baseline and Week 8/Early Withdrawal	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[109]	99 ^[110]	101 ^[111]	107 ^[112]
Units: ratio				
arithmetic mean (standard deviation)				
Baseline, n=97, 98, 96, 102, 95, 103	1.0221 (± 0.00721)	1.0232 (± 0.00762)	1.0217 (± 0.00786)	1.0223 (± 0.00653)
Week 8, n=65, 79, 88, 90, 80, 92	1.0223 (± 0.00633)	1.0214 (± 0.0069)	1.0223 (± 0.0073)	1.023 (± 0.0068)
EW, n=7, 0, 1, 4, 5, 4	1.0203 (± 0.00685)	99999 (± 99999)	1.038 (± 99999)	1.0255 (± 0.00311)

Notes:

[109] - ITT Population. Only those participants available at the specified time points were analyzed.

[110] - ITT Population. Only those participants available at the specified time points were analyzed.

[111] - ITT Population. Only those participants available at the specified time points were analyzed.

[112] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[113]	110 ^[114]		
Units: ratio				
arithmetic mean (standard deviation)				
Baseline, n=97, 98, 96, 102, 95, 103	1.021 (± 0.00692)	1.0218 (± 0.00774)		
Week 8, n=65, 79, 88, 90, 80, 92	1.0214 (± 0.00702)	1.0228 (± 0.00813)		
EW, n=7, 0, 1, 4, 5, 4	1.02 (± 0.00863)	1.0233 (± 0.00506)		

Notes:

[113] - ITT Population. Only those participants available at the specified time points were analyzed.

[114] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Urine pH at Baseline and Week 8/Early Withdrawal

End point title	Urine pH at Baseline and Week 8/Early Withdrawal
End point description:	
<p>Urine samples were collected for the measurement of urine pH by dipstick method at Baseline and at Week 8/Early Withdrawal. The Baseline value was the measurement taken at screening (Visit 1). Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Please note that for the GW685698X 200 µg OD treatment no participants were analyzed; therefore, the value of 99999 which represents NA. Also for the GW685698X 400 µg OD treatment the standard deviation could not be calculated for a single participant; therefore the value of 99999 was entered which represents NA.</p>	
End point type	Secondary

End point timeframe:

Baseline and Week 8/Early Withdrawal

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103 ^[115]	99 ^[116]	101 ^[117]	107 ^[118]
Units: scores on a scale				
arithmetic mean (standard deviation)				
Baseline, n=97, 98, 96, 102, 95, 103	6.01 (± 0.405)	5.93 (± 0.429)	6.01 (± 0.441)	6 (± 0.482)
Week 8, n=65, 79, 88, 90, 80, 92	6.11 (± 0.534)	6 (± 0.416)	5.91 (± 0.469)	5.97 (± 0.494)
EW, n=7, 0, 1, 4, 5, 4	5.71 (± 0.267)	99999 (± 99999)	6 (± 99999)	5.88 (± 0.479)

Notes:

[115] - ITT Population. Only those participants available at the specified time points were analyzed.

[116] - ITT Population. Only those participants available at the specified time points were analyzed.

[117] - ITT Population. Only those participants available at the specified time points were analyzed.

[118] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102 ^[119]	110 ^[120]		
Units: scores on a scale				
arithmetic mean (standard deviation)				
Baseline, n=97, 98, 96, 102, 95, 103	5.92 (± 0.486)	5.88 (± 0.415)		
Week 8, n=65, 79, 88, 90, 80, 92	5.98 (± 0.493)	6.04 (± 0.464)		
EW, n=7, 0, 1, 4, 5, 4	5.6 (± 0.418)	5.88 (± 0.25)		

Notes:

[119] - ITT Population. Only those participants available at the specified time points were analyzed.

[120] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: 24-hour urinary cortisol excretion at Baseline and Week 8

End point title	24-hour urinary cortisol excretion at Baseline and Week 8
End point description: A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at the following scheduled time points: within 7 days prior to Study Visit 3 (Baseline; Week 0) and Study Visit 8 (Week 8). The Baseline value for 24-hour urinary cortisol was taken from Visit 3. Urine Cortisol (UC) Population: all participants whose urine samples did not have confounding factors that could affect the interpretation of results.	
End point type	Secondary
End point timeframe: Baseline and Week 8	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52 ^[121]	71 ^[122]	74 ^[123]	71 ^[124]
Units: Nanomoles per 24 hours (nmol/24 hours)				
median (full range (min-max))				
Baseline	52.55 (5.2 to 273.8)	66 (3.6 to 362)	54.65 (6.3 to 662.4)	67.5 (12.2 to 694.8)
Week 8	51.79 (2.8 to 253.2)	69.4 (4.2 to 244.8)	55.19 (3 to 374.5)	49.8 (4 to 345.4)

Notes:

[121] - UC Population

[122] - UC Population

[123] - UC Population

[124] - UC Population

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	66 ^[125]	80 ^[126]		
Units: Nanomoles per 24 hours (nmol/24 hours)				
median (full range (min-max))				
Baseline	51.3 (9.7 to 182.4)	70.12 (7.4 to 282)		
Week 8	22.99 (2.7 to 252)	62.35 (7.2 to 1441.3)		

Notes:

[125] - UC Population

[126] - UC Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Week 8

End point title	Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Week 8
End point description: Change from Baseline was calculated as the Week 8 value minus the Baseline value.	
End point type	Secondary
End point timeframe: Baseline and Week 8	

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66 ^[127]	82 ^[128]	93 ^[129]	95 ^[130]
Units: Millimeters of mercury (mmHg)				
arithmetic mean (standard deviation)				
SBP	-0.4 (± 11.17)	-1.2 (± 9.96)	-1.9 (± 9.56)	-0.8 (± 11.07)

DBP	1 (± 8.28)	-1 (± 8.36)	-0.9 (± 8.37)	1.7 (± 7.74)
-----	------------	-------------	---------------	--------------

Notes:

[127] - ITT Population. Only those participants available at the specified time points were analyzed.

[128] - ITT Population. Only those participants available at the specified time points were analyzed.

[129] - ITT Population. Only those participants available at the specified time points were analyzed.

[130] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86 ^[131]	97 ^[132]		
Units: Millimeters of mercury (mmHg)				
arithmetic mean (standard deviation)				
SBP	0 (± 11.57)	-2.8 (± 11.32)		
DBP	1.8 (± 8.72)	-1.5 (± 9.48)		

Notes:

[131] - ITT Population. Only those participants available at the specified time points were analyzed.

[132] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in heart rate at Week 8

End point title	Change from Baseline in heart rate at Week 8
End point description:	Change from Baseline was calculated as the Week 8 value minus the Baseline value.
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD	GW685698X 600 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66 ^[133]	82 ^[134]	93 ^[135]	95 ^[136]
Units: Beats per minute				
arithmetic mean (standard deviation)	0.7 (± 8.07)	-0.8 (± 9.4)	0.2 (± 8.89)	-0.1 (± 8.7)

Notes:

[133] - ITT Population. Only those participants available at the specified time points were analyzed.

[134] - ITT Population. Only those participants available at the specified time points were analyzed.

[135] - ITT Population. Only those participants available at the specified time points were analyzed.

[136] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 800 µg OD	FP 500 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86 ^[137]	97 ^[138]		
Units: Beats per minute				
arithmetic mean (standard deviation)	-0.4 (± 8.24)	0 (± 8.6)		

Notes:

[137] - ITT Population. Only those participants available at the specified time points were analyzed.

[138] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the the treatment period (up to Week 8).

Adverse event reporting additional description:

SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of trial medication during the treatment period.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	11
--------------------	----

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Reporting group title	GW685698X 200 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 200 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Reporting group title	GW685698X 400 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Reporting group title	GW685698X 600 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 600 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Reporting group title	GW685698X 800 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 800 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Reporting group title	FP 500 µg BID
-----------------------	---------------

Reporting group description:

Participants received fluticasone propionate (FP) 500 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. Albuterol/salbutamol inhalation aerosol was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.

Serious adverse events	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 103 (0.97%)	2 / 99 (2.02%)	0 / 101 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	0 / 103 (0.00%)	0 / 99 (0.00%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 103 (0.00%)	0 / 99 (0.00%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 103 (0.97%)	0 / 99 (0.00%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 103 (0.00%)	0 / 99 (0.00%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastrointestinal infection			
subjects affected / exposed	0 / 103 (0.00%)	1 / 99 (1.01%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 103 (0.00%)	1 / 99 (1.01%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GW685698X 600 µg OD	GW685698X 800 µg OD	FP 500 µg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 107 (0.93%)	0 / 102 (0.00%)	2 / 110 (1.82%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	0 / 107 (0.00%)	0 / 102 (0.00%)	1 / 110 (0.91%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 107 (0.93%)	0 / 102 (0.00%)	0 / 110 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 107 (0.00%)	0 / 102 (0.00%)	1 / 110 (0.91%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 107 (0.00%)	0 / 102 (0.00%)	1 / 110 (0.91%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastrointestinal infection			
subjects affected / exposed	0 / 107 (0.00%)	0 / 102 (0.00%)	0 / 110 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 102 (0.00%)	0 / 110 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Placebo	GW685698X 200 µg OD	GW685698X 400 µg OD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 103 (14.56%)	18 / 99 (18.18%)	21 / 101 (20.79%)
Nervous system disorders			
Headache			
subjects affected / exposed	10 / 103 (9.71%)	3 / 99 (3.03%)	10 / 101 (9.90%)
occurrences (all)	15	3	13
Respiratory, thoracic and mediastinal disorders			
Pharyngolaryngeal pain			
subjects affected / exposed	1 / 103 (0.97%)	2 / 99 (2.02%)	0 / 101 (0.00%)
occurrences (all)	1	2	0
Dysphonia			
subjects affected / exposed	1 / 103 (0.97%)	4 / 99 (4.04%)	5 / 101 (4.95%)
occurrences (all)	1	4	5
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 103 (0.97%)	1 / 99 (1.01%)	1 / 101 (0.99%)
occurrences (all)	1	1	1
Infections and infestations			
Oral candidiasis			
subjects affected / exposed	0 / 103 (0.00%)	2 / 99 (2.02%)	2 / 101 (1.98%)
occurrences (all)	0	2	3
Oropharyngeal candidiasis			
subjects affected / exposed	1 / 103 (0.97%)	4 / 99 (4.04%)	4 / 101 (3.96%)
occurrences (all)	1	5	5
Nasopharyngitis			
subjects affected / exposed	4 / 103 (3.88%)	3 / 99 (3.03%)	5 / 101 (4.95%)
occurrences (all)	5	3	6

Non-serious adverse events	GW685698X 600 µg OD	GW685698X 800 µg OD	FP 500 µg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 107 (19.63%)	26 / 102 (25.49%)	21 / 110 (19.09%)
Nervous system disorders			
Headache			
subjects affected / exposed	12 / 107 (11.21%)	10 / 102 (9.80%)	10 / 110 (9.09%)
occurrences (all)	25	19	12
Respiratory, thoracic and mediastinal disorders			
Pharyngolaryngeal pain			
subjects affected / exposed	3 / 107 (2.80%)	1 / 102 (0.98%)	4 / 110 (3.64%)
occurrences (all)	6	2	4
Dysphonia			
subjects affected / exposed	1 / 107 (0.93%)	4 / 102 (3.92%)	2 / 110 (1.82%)
occurrences (all)	1	4	2
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	4 / 107 (3.74%)	2 / 102 (1.96%)	0 / 110 (0.00%)
occurrences (all)	4	3	0
Infections and infestations			
Oral candidiasis			
subjects affected / exposed	1 / 107 (0.93%)	7 / 102 (6.86%)	0 / 110 (0.00%)
occurrences (all)	1	7	0
Oropharyngeal candidiasis			
subjects affected / exposed	1 / 107 (0.93%)	4 / 102 (3.92%)	4 / 110 (3.64%)
occurrences (all)	1	6	4
Nasopharyngitis			
subjects affected / exposed	2 / 107 (1.87%)	7 / 102 (6.86%)	4 / 110 (3.64%)
occurrences (all)	2	8	4

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 September 2007	To correct a typographical error in the document number on the Sponsor Signatory Page; to provide additional details on PGx blood sampling (Protocol Summary, Pharmacogenetics Sampling, Section 6.5, Table 1); to correct typographical error concerning pregnancy tests (Section 4.2); to remove statement on subjects who are screen failures (Section 4.5); to add statement to study treatments footnote number 1 (Section 5.1); to clarify non asthma medications (Section 5.6.1.); to clarify the fasting laboratory assessment (footnote number 7) is only for clinical chemistry (Table 1); to clarify that PK sampling is at Visits 5 and 8 only and not at the Early Withdrawal Visit (Table 1); to clarify that the FEV1 to be performed at Visits 1 and 3 through 8 (Section 6.2.1); to clarify the visits for oropharynx exam and vital signs (Protocol Summary, Section 6.3.1.); to clarify that AE collection starts at Visit 3 (Section 6.3.4); to clarify the Visits for the physical exam (Section 6.3.8.1); to clarify the IP collection at Visit 6, 8 or Early Withdrawal (Table 1); corrected typographical error for SAE (Section 6.3.7.); corrected typographical error on visit number for baseline values (Section 8.3.5.); to change the reference from "electronic" Daily Diary (or eDiary) to Daily Diary (Protocol Summary - Study Design, Section 3.1., Section 4.2., Section 4.3.2., Section 4.4.1., Section 6.2.2., Section 6.2.2.1. and Section 6.3.4.); to clarify the list of abbreviations; to remove the sentence in Appendix 1: Pharmacogenetic Research (PGx) (Section 11); to clarify inclusion and exclusion criteria for randomization to treatment (Section 4.3.1 and Section 4.3.2. number 6); to remove statement on medical dictionary use (Section 7); to correct typographical errors throughout the document.
24 October 2007	To change once daily GW685698X administration from morning to evening and to amend timing of measures that are impacted by this change (i.e. FEV1, PK,) To amend entry criterion % predicted normal FEV1 range. To up-date NIH reference from 2002 to 2007. To include reference to IB Supplement. To clarify when vital sign assessments will occur
06 December 2007	To amend Inclusion Criterion number 7, anti-asthma therapy. To amend IP compliance at Visit 6. To clarify the Lung Function reversibility procedure. To clarify the Urinary Coritsol Population.
21 March 2008	To adjust the FEV1 entry criteria depending on the time of day the screening period is conducted. To allow subjects to re-screen for Visit 1 if they fail to meet lung function criteria. To clarify the exclusion of subjects with upper and lower respiratory tract infections at Visit 1 and Visit 3 (Randomization to Treatment). To allow the use of long acting anti-histamines

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

